{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,4]],"date-time":"2026-03-04T00:46:12Z","timestamp":1772585172278,"version":"3.50.1"},"reference-count":105,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2016,7,7]],"date-time":"2016-07-07T00:00:00Z","timestamp":1467849600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2016,7,7]],"date-time":"2016-07-07T00:00:00Z","timestamp":1467849600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Treat Options Gastro"],"published-print":{"date-parts":[[2016,9]]},"DOI":"10.1007\/s11938-016-0099-6","type":"journal-article","created":{"date-parts":[[2016,7,7]],"date-time":"2016-07-07T05:59:07Z","timestamp":1467871147000},"page":"285-304","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":22,"title":["Management of Inflammatory Bowel Disease in the Elderly"],"prefix":"10.1007","volume":"14","author":[{"given":"Elizabeth S.","family":"John","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kristina","family":"Katz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark","family":"Saxena","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sita","family":"Chokhavatia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seymour","family":"Katz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2016,7,7]]},"reference":[{"key":"99_CR1","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1007\/s10620-012-2371-5","volume":"58","author":"MD Kappelman","year":"2013","unstructured":"Kappelman MD, Moore KR, Allen JK, Cook SF. Recent trends in the prevalence of Crohn\u2019s disease and ulcerative colitis in a commercially insured US population. Dig Dis Sci. 2013;58:519\u201325.","journal-title":"Dig Dis Sci"},{"key":"99_CR2","doi-asserted-by":"publisher","first-page":"617","DOI":"10.2165\/11537340-000000000-00000","volume":"27","author":"SW Hussain","year":"2010","unstructured":"Hussain SW, Pardi DS. Inflammatory bowel disease in the elderly. Drugs Aging. 2010;27:617\u201324.","journal-title":"Drugs Aging"},{"key":"99_CR3","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1136\/gut.46.3.336","volume":"46","author":"EV Loftus Jr","year":"2000","unstructured":"Loftus Jr EV, Silverstein MD, Sandborn WJ, et al. Ulcerative colitis in Olmsted County, Minnesota, 1940\u20131993: incidence, prevalence, and survival. Gut. 2000;46:336\u201343.","journal-title":"Gut"},{"key":"99_CR4","doi-asserted-by":"crossref","first-page":"2734","DOI":"10.3748\/wjg.v17.i22.2734","volume":"17","author":"JH del Val","year":"2011","unstructured":"del Val JH. Old age inflammatory bowel disease onset: a different problem? World J Gastroenterol. 2011;17:2734\u20139.","journal-title":"World J Gastroenterol"},{"key":"99_CR5","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1002\/ibd.20029","volume":"13","author":"CG Loftus","year":"2007","unstructured":"Loftus CG, Loftus Jr EV, Harmsen WS, et al. Update on the incidence and prevalence of Crohn\u2019s disease and ulcerative colitis in Olmsted County, Minnesota, 1940\u20132000. Inflamm Bowel Dis. 2007;13:254\u201361.","journal-title":"Inflamm Bowel Dis"},{"key":"99_CR6","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1016\/j.crohns.2010.08.004","volume":"5","author":"PL Lakatos","year":"2011","unstructured":"Lakatos PL, David G, Pandur T, et al. IBD in the elderly population: results from a population-based study in Western Hungary, 1977-2008. J Crohns Colitis. 2011;5:5\u201313. This study conducted in Western Hungary investigated the incidence and course of IBD with respect to age. They found that in the 1420 incident patients, the prevalence of IBD in the elderly population was increasing with distinct characteristics of CD and UC in the elderly.","journal-title":"J Crohns Colitis"},{"key":"99_CR7","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1136\/gutjnl-2012-303864","volume":"63","author":"C Charpentier","year":"2014","unstructured":"Charpentier C, Salleron J, Savoye G, et al. Natural history of elderly-onset inflammatory bowel disease: a population-based cohort study. Gut. 2014;63:423\u201332. This French based study specifically looked at elderly-onset IBD, and found that the course of IBD is milder in elderly patients, specifically greater than 60 years of age.","journal-title":"Gut"},{"key":"99_CR8","unstructured":"Gudsoorkar VS, Abraham B. Inflammatory bowel disease in the elderly: hazards of generalizing the evidence. Pract Gastroenterol. 2015: 26-40."},{"key":"99_CR9","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1038\/ajg.2009.727","volume":"105","author":"A Kornbluth","year":"2010","unstructured":"Kornbluth A, Sachar DB. Ulcerative colitis practice guidelines in adults: American College of Gastroeneterology, Practice Parameters Committee. Am J Gastroenterol. 2010;105:501\u201323.","journal-title":"Am J Gastroenterol"},{"key":"99_CR10","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1038\/ajg.2008.168","volume":"104","author":"GR Lichenstein","year":"2009","unstructured":"Lichenstein GR, Hanauer SB, Sandborn WJ. Management of Crohn\u2019s disease in adults. Am J Gastroenterol. 2009;104:465\u201383.","journal-title":"Am J Gastroenterol"},{"key":"99_CR11","doi-asserted-by":"publisher","first-page":"1889","DOI":"10.1038\/ajg.2011.271","volume":"106","author":"S Katz","year":"2011","unstructured":"Katz S, Pardi DS. Inflammatory bowel disease of the elderly: frequently asked questions (FAQs). Am J Gastroenterol. 2011;106:1889\u201397.","journal-title":"Am J Gastroenterol"},{"issue":"5","key":"99_CR12","doi-asserted-by":"publisher","first-page":"1132","DOI":"10.1007\/s10620-014-3462-2","volume":"60","author":"DL Shung","year":"2015","unstructured":"Shung DL, Abraham B, Sellin J, Hou JK. Medical and surgical complications of inflammatory bowel disease in the elderly: a systematic review. Dig Dis Sci. 2015;60(5):1132\u201340.","journal-title":"Dig Dis Sci"},{"issue":"1","key":"99_CR13","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1080\/08998280.2006.11928114","volume":"19","author":"JS Fordtran","year":"2006","unstructured":"Fordtran JS. Colitis due to C.diff toxins, underdiagnosed, highly virulent, and nosocomial. Proc (Baylor Univ Med Cent). 2006;19(1):3\u201312.","journal-title":"Proc (Baylor Univ Med Cent)"},{"key":"99_CR14","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1016\/j.jamcollsurg.2014.01.053","volume":"218","author":"CE Collins","year":"2014","unstructured":"Collins CE, Ayturk MD, Flahive JM, et al. Epidemiology and outcomes of community-acquired Clostridium difficile infections in medicare beneficiaries. J Am Coll Surg. 2014;218:1141\u20137.","journal-title":"J Am Coll Surg"},{"key":"99_CR15","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1053\/j.gastro.2013.04.007","volume":"145","author":"SC Ng","year":"2013","unstructured":"Ng SC, Tang W, Ching JY, et al. Incidence and phenotype of inflammatory bowel disease based on results from the Asia-pacific Crohn\u2019s and colitis epidemiology study. Gastroenterology. 2013;145:158\u201365.","journal-title":"Gastroenterology"},{"key":"99_CR16","doi-asserted-by":"publisher","first-page":"3183","DOI":"10.3748\/wjg.14.3183","volume":"14","author":"M Hadithi","year":"2008","unstructured":"Hadithi M, Cazemier M, Meijer GA, et al. Retrospective analysis of old-age colitis in the Dutch inflammatory bowel disease population. World J Gastroenterol. 2008;14:3183\u20137.","journal-title":"World J Gastroenterol"},{"issue":"2","key":"99_CR17","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1080\/03602530902722679","volume":"41","author":"U Klotz","year":"2009","unstructured":"Klotz U. Pharmacokinetics and drug metabolism in the elderly. Drug Metab Rev. 2009;41(2):67\u201376.","journal-title":"Drug Metab Rev"},{"key":"99_CR18","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1007\/s11938-015-0059-6","volume":"13","author":"S Taleban","year":"2015","unstructured":"Taleban S. Challenges in the diagnosis and management of inflammatory bowel disease in the elderly. Curr Treat Options Gastro. 2015;13:275\u201386.","journal-title":"Curr Treat Options Gastro"},{"key":"99_CR19","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.1016\/j.clinbiochem.2014.01.003","volume":"47","author":"T Nilsen","year":"2014","unstructured":"Nilsen T, Sundstr\u00f6m J, Lind L, et al. Serum calprotectin levels in elderly males and females without bacterial or viral infections. Clin Biochem. 2014;47:1065\u20138.","journal-title":"Clin Biochem"},{"key":"99_CR20","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1258\/acb.2009.009061","volume":"47","author":"S Joshi","year":"2010","unstructured":"Joshi S, Lewis SJ, Creanor S, et al. Age-related faecal calprotectin, lactoferrin and tumour M2-PK concentrations in healthy volunteers. Ann Clin Biochem. 2010;47:259\u201363.","journal-title":"Ann Clin Biochem"},{"key":"99_CR21","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1016\/S1091-255X(01)00060-9","volume":"6","author":"MJ Page","year":"2002","unstructured":"Page MJ, Poritz LS, Kunselman SJ, et al. Factors affecting surgical risk in elderly patients with inflammatory bowel disease. J Gastrointest Surg. 2002;6:606\u201313.","journal-title":"J Gastrointest Surg"},{"issue":"12","key":"99_CR22","doi-asserted-by":"publisher","first-page":"3080","DOI":"10.1007\/s10620-012-2289-y","volume":"57","author":"C Gunnarsson","year":"2012","unstructured":"Gunnarsson C, Chen J, Rizzo JA, Ladapo JA, Lofland JH. Direct health care insurer and out-of-pocket expenditures of inflammatory bowel disease: evidence from a US national survey. Dig Dis Sci. 2012;57(12):3080\u201391.","journal-title":"Dig Dis Sci"},{"key":"99_CR23","unstructured":"Lexicomp Online\u00ae, Hudson, Ohio: Lexi-Comp, Inc.; 2015."},{"key":"99_CR24","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1136\/gut.52.2.172","volume":"52","author":"CG Loftus","year":"2003","unstructured":"Loftus CG, Loftus Jr EV, Sandborn WJ. Cyclosporin for refractory ulcerative colitis. Gut. 2003;52:172\u20133.","journal-title":"Gut"},{"key":"99_CR25","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1159\/000228569","volume":"27","author":"AN Ananthakrishnan","year":"2009","unstructured":"Ananthakrishnan AN, Binion D. Treatment of ulcerative colitis in the elderly. Dig Dis. 2009;27:327\u201334.","journal-title":"Dig Dis"},{"key":"99_CR26","doi-asserted-by":"publisher","unstructured":"Vagianos K, Clara I, Carr R, et al. What are adults with inflammatory nowel disease (IBD) eating? A closer look at the dietary habits of a population-based Canadian IBD cohort. JPEN J Parenter Enteral Nutr. pii 10.1177\/0148607114549254","DOI":"10.1177\/0148607114549254"},{"key":"99_CR27","doi-asserted-by":"crossref","unstructured":"Lee J, Allen R, Ashley S. British Dietetic Association evidence-based guidelines for the dietary management of Crohn\u2019s disease in adults. J Hum Nutr Diet. 27(3): 207-18.","DOI":"10.1111\/jhn.12176"},{"key":"99_CR28","doi-asserted-by":"crossref","unstructured":"Martin GS, Tapsell LC, Denmeade S. Relative validity of a diet history interview in an intervention trial manipulating dietary fat in the management of Type II diabetes mellitus. Prev Med. 36(4): 420-8.","DOI":"10.1016\/S0091-7435(02)00054-3"},{"key":"99_CR29","doi-asserted-by":"publisher","first-page":"953","DOI":"10.1002\/ibd.21152","volume":"16","author":"B Pigneur","year":"2010","unstructured":"Pigneur B, Seksik P, Viola S, Viala J, Beaugerie L, Girardet JP, et al. Natural history of Crohn\u2019s disease: comparison between childhood- and adult-onset disease. Inflamm Bowel Dis. 2010;16:953\u201361.","journal-title":"Inflamm Bowel Dis"},{"issue":"6","key":"99_CR30","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1093\/ecco-jcc\/jjv059","volume":"9","author":"S Taleban","year":"2015","unstructured":"Taleban S, Colombel JF, Mohler MJ, Fain MJ. Inflammatory bowel disease and the elderly: a review. J Crohns Colitis. 2015;9(6):507\u201315. This recent review delineates the growing incidence and prevalence of IBD in the elderly, highlights the different pathophysiologies and clinical manifestations between younger and older patients, and reviews the medical and surgical managements of elderly adults with IBD.","journal-title":"J Crohns Colitis"},{"key":"99_CR31","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1097\/FTD.0b013e3182731925","volume":"34","author":"Z Fangbin","year":"2012","unstructured":"Fangbin Z, Xiang G, Minhu C, et al. Should thiopurine methyltransferase genotypes and phenotypes be measured before thiopurine therapy in patients with inflammatory bowel disease? Ther Drug Monit. 2012;34:695\u2013701.","journal-title":"Ther Drug Monit"},{"key":"99_CR32","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1359\/JBMR.040134","volume":"19","author":"JA Kanis","year":"2004","unstructured":"Kanis JA, Johansson H, Oden A, et al. A meta-analysis of prior corticosteroid use and fracture risk. J Bone Miner Res. 2004;19:893\u20139.","journal-title":"J Bone Miner Res"},{"key":"99_CR33","doi-asserted-by":"publisher","first-page":"2408","DOI":"10.1007\/s10620-012-2083-x","volume":"57","author":"M Juneja","year":"2012","unstructured":"Juneja M, Maidoo L, Schwartz MB, Barrie 3rd A, Regueiro M, Dunn M, et al. Geriatric inflammatory bowel disease: phenotypic presentation, treatment patterns, nutritional status, outcomes, and comorbidity. Dig Dis Sci. 2012;57:2408\u201315.","journal-title":"Dig Dis Sci"},{"key":"99_CR34","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1111\/j.0105-2896.2005.00263.x","volume":"205","author":"H Min","year":"2005","unstructured":"Min H, Montecino-Rodriguez E, Dorshkind K. Effects of aging on early B- and T-cell development. Immunol Rev. 2005;205:7\u201317.","journal-title":"Immunol Rev"},{"key":"99_CR35","first-page":"716","volume":"129","author":"G D-Haens","year":"1998","unstructured":"D-Haens G, Verstraete A, Cheyns K, et al. Bone turnover during short-term therapy with methylprednisolone or budesonide in Crohn\u2019s disease. Aliment Pharmacol Ther. 1998;129:716\u20138.","journal-title":"Aliment Pharmacol Ther"},{"key":"99_CR36","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1056\/NEJM199409293311304","volume":"331","author":"P Rutgeerts","year":"1994","unstructured":"Rutgeerts P, Lofberg R, Malchow H, et al. A comparison of budesonide with prednisolone for active Crohn\u2019s disease. N Engl J Med. 1994;331:842\u20135.","journal-title":"N Engl J Med"},{"key":"99_CR37","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.1093\/ajcn\/82.6.1346","volume":"82","author":"MI Ramos","year":"2005","unstructured":"Ramos MI, Allen LH, Mungas DM, et al. Low folate status is associated with impaired cognitive function and dementia in the Sacramento Area Latino Study on Ageing. Am J Clin Nutr. 2005;82:1346\u201352.","journal-title":"Am J Clin Nutr"},{"key":"99_CR38","first-page":"163","volume":"109","author":"B Shea","year":"2014","unstructured":"Shea B, Swinden MV, Tanjon Ghogomu E, et al. Folic acid and folinic acid for reducing side effects in patients receiving methotrexate fur rheumatoid arthritis. J Rheumatol. 2014;109:163\u20139.","journal-title":"J Rheumatol"},{"key":"99_CR39","volume-title":"Cytotoxic agents. Goodman and Gilman\u2019s the pharmacological basis of therapeutics","author":"J Bertino","year":"2011","unstructured":"Bertino J, Cleary J, Ortiz T, Lane A, Supko JG, Ryan D. Cytotoxic agents. Goodman and Gilman\u2019s the pharmacological basis of therapeutics. 12th ed. New York: McGraw-Hill Global Education Holdings; 2011.","edition":"12"},{"issue":"3","key":"99_CR40","doi-asserted-by":"publisher","first-page":"194","DOI":"10.2165\/00003088-199630030-00002","volume":"30","author":"B Bannwarth","year":"1996","unstructured":"Bannwarth B, P\u00e9hourcq F, Schaeverbeke T, Dehais J. Clinical pharmacokinetics of low-dose pulse methotrexate in rheumatoid arthritis. Clin Pharmacokinet. 1996;30(3):194\u2013210.","journal-title":"Clin Pharmacokinet"},{"key":"99_CR41","volume-title":"Methotrexate. Applied pharmacokinetics: principles of therapeutic drug monitoring","author":"WR Crom","year":"1992","unstructured":"Crom WR, Evan WE. Methotrexate. Applied pharmacokinetics: principles of therapeutic drug monitoring. 3rd ed. New York: Lippincott Williams & Wilkins; 1992.","edition":"3"},{"issue":"1","key":"99_CR42","first-page":"53","volume":"60","author":"J Cudmore","year":"2014","unstructured":"Cudmore J, Seftel M, Sisler J, Zarychanski R. Methotrexate and trimethoprim-sulfamethoxazole toxicity from this combination continues to occur. Can Fam Physician. 2014;60(1):53\u20136.","journal-title":"Can Fam Physician"},{"key":"99_CR43","doi-asserted-by":"publisher","first-page":"1416","DOI":"10.3899\/jrheum.090153","volume":"37","author":"J Bourre-Tessier","year":"2010","unstructured":"Bourre-Tessier J, Haraoui B. Methotrexate drug interactions in the treatment of rheumatoid arthritis: a systematic review. J Rheumatol. 2010;37:1416\u201321.","journal-title":"J Rheumatol"},{"key":"99_CR44","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1016\/j.jamcollsurg.2006.08.026","volume":"203","author":"FE Turrentine","year":"2006","unstructured":"Turrentine FE, Wang H, Simpson VB, et al. Surgical risk factors, morbidity, and mortality in elderly patients. J Am Coll Surg. 2006;203:865\u201377.","journal-title":"J Am Coll Surg"},{"key":"99_CR45","doi-asserted-by":"publisher","first-page":"187","DOI":"10.2165\/00003088-200746030-00001","volume":"46","author":"A Teml","year":"2007","unstructured":"Teml A, Schaeffeler E, Herrlinger KR, et al. Thiopurine treatment in inflammatory bowel disease: clinical pharmacology and implication of pharmacogenetically guided dosing. Clin Pharmacokinet. 2007;46:187\u2013208.","journal-title":"Clin Pharmacokinet"},{"key":"99_CR46","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1002\/ibd.23021","volume":"19","author":"F Hoentjen","year":"2013","unstructured":"Hoentjen F, Seinen ML, Hanauer SB, et al. Safety and effectiveness of long-term allopurinol-thiopurine maintenance treatment in inflammatory bowel disease. Inflamm Bowel Dis. 2013;19:363\u20139.","journal-title":"Inflamm Bowel Dis"},{"key":"99_CR47","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1111\/j.1572-0241.2007.01559.x","volume":"103","author":"PM Irving","year":"2008","unstructured":"Irving PM, Shanahan F, Rampton DS. Drug interactions in inflammatory bowel disease. Am J Gastroenterol. 2008;103:207\u201319.","journal-title":"Am J Gastroenterol"},{"key":"99_CR48","doi-asserted-by":"crossref","unstructured":"Khan N, Abbas AM, Lichtenstein GR, et al. Risk of lymphoma in patients with ulcerative colitis treated with thiopurines: a nationwide retrospective cohort study. Gastroenterology. 2013; 145-1007-15.","DOI":"10.1053\/j.gastro.2013.07.035"},{"key":"99_CR49","doi-asserted-by":"publisher","first-page":"874","DOI":"10.1016\/j.cgh.2009.01.004","volume":"7","author":"CA Siegel","year":"2009","unstructured":"Siegel CA, Marden SM, Persing SM, et al. Risk of lymphoma associated with combination anti-tumor necrosis factor and immunomodulator therapy for the treatment of Crohn\u2019s disease: a meta-analysis. Clin Gastroenterol Hepatol. 2009;7:874\u201381.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"99_CR50","unstructured":"Mehmood F, Wysocki J, Serper M, et al. Efficacy and safety of thiopurine therapy in patients with elderly onset ulcerative colitis. Aliment Pharma Ther. 2015."},{"key":"99_CR51","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1053\/j.gastro.2012.05.004","volume":"143","author":"MD Long","year":"2012","unstructured":"Long MD, Martin CF, Pipkin CA, et al. Risk of melanoma and nonmelanoma skin cancer among patients with inflammatory bowel disease. Gastroenterology. 2012;143:390\u20139.","journal-title":"Gastroenterology"},{"key":"99_CR52","doi-asserted-by":"crossref","unstructured":"Kopylov U, Vutcovici M, Kezouh A, Seidman E, Bitton A, Afif W. Risk of lymphoma, colorectal and skin cancer in patients with IBD treated with immunomodulators and biologics: a Quebec Claims Database Study. Inflamm Bowel Dis. 2015.","DOI":"10.1097\/MIB.0000000000000457"},{"key":"99_CR53","doi-asserted-by":"publisher","first-page":"2063","DOI":"10.1002\/ibd.22889","volume":"18","author":"H Sokol","year":"2012","unstructured":"Sokol H, Beaugerie L, Maynadie M, et al. Excess primary intestinal lymphoproliferative disorders in patients with inflammatory bowel disease. Inflamm Bowel Dis. 2012;18:2063\u201371.","journal-title":"Inflamm Bowel Dis"},{"issue":"Suppl 1","key":"99_CR54","doi-asserted-by":"publisher","first-page":"S3","DOI":"10.1016\/S1873-9946(14)60006-4","volume":"8","author":"S Jeuring","year":"2014","unstructured":"Jeuring S, Van den Heuvel T, Zeegers M, et al. Is elderly-onset ulcerative colitis a different entity?\u2014natural disease course and treatment response compared to adult-onset disease in the population-based IBD-SL cohort. J Crohns Colitis. 2014;8 Suppl 1:S3\u20134.","journal-title":"J Crohns Colitis"},{"key":"99_CR55","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1038\/ajg.2013.451","volume":"109","author":"J Ariyaratnam","year":"2014","unstructured":"Ariyaratnam J, Subramanian V. Association between thiopurine use and nonmelanoma skin cancers in patients with inflammatory bowel disease: a meta-analysis. Am J Gastroenterol. 2014;109:163\u20139.","journal-title":"Am J Gastroenterol"},{"key":"99_CR56","doi-asserted-by":"publisher","first-page":"1404","DOI":"10.1097\/MIB.0b013e318281f28f","volume":"19","author":"M Chaparro","year":"2013","unstructured":"Chaparro M, Ordas I, Cabre E, et al. Safety of thiopurine therapy in inflammatory bowel disease; long-term follow up study of 3931 patients. Inflamm Bowel Dis. 2013;19:1404\u201310.","journal-title":"Inflamm Bowel Dis"},{"issue":"5","key":"99_CR57","doi-asserted-by":"publisher","first-page":"355","DOI":"10.2165\/00002512-200219050-00004","volume":"19","author":"DS Pardi","year":"2002","unstructured":"Pardi DS, Loftus Jr EV, Camilleri M. Treatment of inflammatory bowel disease in the elderly: an update. Drugs Aging. 2002;19(5):355\u201363.","journal-title":"Drugs Aging"},{"issue":"9","key":"99_CR58","first-page":"1424","volume":"92","author":"A Kornbluth","year":"1997","unstructured":"Kornbluth A, Present DH, Lichtiger S, Hanauer S. Cyclosporin for severe ulcerative colitis: a user\u2019s guide. Am J Gastroenterol. 1997;92(9):1424\u20138.","journal-title":"Am J Gastroenterol"},{"key":"99_CR59","doi-asserted-by":"crossref","unstructured":"Lobaton T, Ferrante M, Rutgeerts P, Ballet V, Van Assche G, Vermeire S. Efficacy and safety of anti-TNF therapy in elderly patients with inflammatory bowel disease. Aliment Pharmacol Ther. 2015.","DOI":"10.1111\/apt.13294"},{"key":"99_CR60","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1002\/ibd.20054","volume":"13","author":"M Ferrante","year":"2007","unstructured":"Ferrante M, Vermeire S, Katsanos KH, Noman M, Van Assche G, Schnitzler F, et al. Predictors of early response to infliximab in patients with ulcerative colitis. Inflamm Bowel Dis. 2007;13:123\u20138.","journal-title":"Inflamm Bowel Dis"},{"issue":"2","key":"99_CR61","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1002\/ibd.23026","volume":"19","author":"A Desai","year":"2013","unstructured":"Desai A, Zator ZA, de Silva P, Nguyen DD, Korzenik J, Yajnik V, et al. Older age is associated with higher rate of discontinuation of anti-TNF therapy in patients with inflammatory bowel disease. Inflamm Bowel Dis. 2013;19(2):309\u201315.","journal-title":"Inflamm Bowel Dis"},{"issue":"3","key":"99_CR62","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1111\/j.1365-2036.2009.04027.x","volume":"30","author":"GR Lichtenstein","year":"2009","unstructured":"Lichtenstein GR, Diamond RH, Wagner CL, Fasanmade AA, Olson AD, Marano CW, et al. Clinical trial: benefits and risks of immunomodulators and maintenance infliximab for IBD-subgroup analyses across four randomized trials. Aliment Pharmacol Ther. 2009;30(3):210\u201326.","journal-title":"Aliment Pharmacol Ther"},{"issue":"15","key":"99_CR63","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.1056\/NEJMoa0904492","volume":"362","author":"JF Colombel","year":"2010","unstructured":"Colombel JF, Sandborn WJ, Reinisch W, Mantzaris GJ, Kornbluth A, Rachmilewitz D, et al. Infliximab, azathioprine, or combination therapy for Crohn\u2019s disease. N Engl J Med. 2010;362(15):1383\u201395.","journal-title":"N Engl J Med"},{"issue":"4","key":"99_CR64","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1136\/gut.2008.155812","volume":"58","author":"F Schnitzler","year":"2009","unstructured":"Schnitzler F, Fidder H, Ferrante M, Noman M, Arijs I, Van Assche G, et al. Long-term outcome of treatment with infliximab in 614 patients with Crohn\u2019s disease: results from a single-centre cohort. Gut. 2009;58(4):492\u2013500.","journal-title":"Gut"},{"key":"99_CR65","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1002\/ibd.21792","volume":"18","author":"K Clarke","year":"2012","unstructured":"Clarke K, Regueiro M. Stopping immunomodulators and biologics in inflammatory bowel disease patients in remission. Inflamm Bowel Dis. 2012;18:174\u20139.","journal-title":"Inflamm Bowel Dis"},{"key":"99_CR66","doi-asserted-by":"publisher","first-page":"1861","DOI":"10.1053\/j.gastro.2008.03.004","volume":"134","author":"G Van Assche","year":"2008","unstructured":"Van Assche G, Magdelaine-Beuzelin C, D\u2019Haens G, et al. Withdrawal of immunosuppression in Crohn\u2019s disease treated with scheduled infliximab maintenance: a randomized trial. Gastroenterology. 2008;134:1861\u20138.","journal-title":"Gastroenterology"},{"key":"99_CR67","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1016\/j.cgh.2010.09.026","volume":"9","author":"M Cottone","year":"2011","unstructured":"Cottone M, Kohn A, Daperno M, Armuzzi A, Guidi L, D\u2019Inca R, et al. Advanced age is an independent risk factor for severe infections and mortality in patients given anti-tumor necrosis factor therapy for inflammatory bowel disease. Clin Gastroenterol Hepatol. 2011;9:30\u20135.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"99_CR68","doi-asserted-by":"publisher","first-page":"312","DOI":"10.3109\/00365521.2014.1000960","volume":"50","author":"JM Byun","year":"2015","unstructured":"Byun JM, Lee CK, Rhee SY, et al. Risks for opportunistic tuberculosis infection in a cohort of 873 patients with inflammatory bowel disease receiving a tumor necrosis factor-alpha inhibitor. Scand J Gastroenterol. 2015;50:312\u201320.","journal-title":"Scand J Gastroenterol"},{"key":"99_CR69","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1007\/s11938-014-0024-9","volume":"12","author":"M Kim","year":"2014","unstructured":"Kim M, Dam A, Green J. Common GI drug interactions in the elderly. Curr Treat Options Gastroenterol. 2014;12:292\u2013309.","journal-title":"Curr Treat Options Gastroenterol"},{"issue":"3","key":"99_CR70","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1016\/j.gtc.2014.05.010","volume":"43","author":"PS Dulai","year":"2014","unstructured":"Dulai PS, Siegel CA. The risk of malignancy associated with the use of biological agents in patients with inflammatory bowel disease. Gastroenterol Clin N Am. 2014;43(3):525\u201341.","journal-title":"Gastroenterol Clin N Am"},{"key":"99_CR71","doi-asserted-by":"publisher","first-page":"1895","DOI":"10.1136\/ard.2010.149419","volume":"70","author":"X Mariette","year":"2011","unstructured":"Mariette X, Matucci-Cerinic M, Pavelka K, et al. Malignancies associated with tumour necrosis factor inhibitors in registries and prospective observational studies: a systemic review and meta-analysis. Ann Rheum Dis. 2011;70:1895\u2013904.","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"99_CR72","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1038\/ajg.2013.441","volume":"109","author":"GR Lichtenstein","year":"2014","unstructured":"Lichtenstein GR, Feagan BG, Cohen RD, et al. Drug therapies and the risk of malignancy in Crohn\u2019s disease: results from the TREAT registry. Am J Gastroenterol. 2014;109(2):212\u201323.","journal-title":"Am J Gastroenterol"},{"key":"99_CR73","doi-asserted-by":"publisher","first-page":"1121","DOI":"10.1136\/gut.2004.049460","volume":"54","author":"A Kandiel","year":"2005","unstructured":"Kandiel A, Fraser AG, Korelitz BI, et al. Increased risk of lymphoma among inflammatory bowel disease patients treated with azathioprine and 6-mercaptopurine. Gut. 2005;54:1121\u20135.","journal-title":"Gut"},{"issue":"1","key":"99_CR74","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/j.cgh.2015.07.037","volume":"14","author":"J Axelrad","year":"2016","unstructured":"Axelrad J, Bernheim O, Colombel JF, Malerba S, Ananthakrishnan A, Yajnik V, et al. Risk of new or recurrent cancer in patients with inflammatory bowel disease and previous cancer exposed to immunosuppressive and anti-tumor necrosis factor agents. Clin Gastroenterol Hepatol. 2016;14(1):58\u201364.","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"23","key":"99_CR75","doi-asserted-by":"publisher","first-page":"2406","DOI":"10.1001\/jama.2014.5613","volume":"311","author":"A Nyboe","year":"2014","unstructured":"Nyboe A, Pasternak B, Basit S, Andersson M, Svanstr\u00f6m H, Caspersen S, et al. Association between tumor necrosis factor-\u03b1 antagonists and risk of cancer in patients with inflammatory bowel disease. JAMA. 2014;311(23):2406\u201313.","journal-title":"JAMA"},{"key":"99_CR76","doi-asserted-by":"publisher","first-page":"1617","DOI":"10.1016\/S0140-6736(09)61302-7","volume":"374","author":"L Beaugerie","year":"2009","unstructured":"Beaugerie L, Brousse N, Bouvier AM, et al. Lymphoproliferative disorders in patients receiving thiopurines for inflammatory bowel disease: a prospective observational cohort study. Lancet. 2009;374:1617\u201325.","journal-title":"Lancet"},{"issue":"4","key":"99_CR77","doi-asserted-by":"publisher","first-page":"1040","DOI":"10.1002\/art.20164","volume":"50","author":"D Khanna","year":"2004","unstructured":"Khanna D, McMahon M, Furst DE. Anti-tumor necrosis factor alpha therapy and heart failure: what have we learned and where do we go from here? Arthritis Rheum. 2004;50(4):1040\u201350.","journal-title":"Arthritis Rheum"},{"issue":"9","key":"99_CR78","doi-asserted-by":"publisher","first-page":"883","DOI":"10.2217\/imt.12.85","volume":"4","author":"LP McLean","year":"2012","unstructured":"McLean LP, Shea-Donohue T, Cross RK. Vedolizumab for the treatment of ulcerative colitis and Crohn\u2019s disease. Immunotherapy. 2012;4(9):883\u201398.","journal-title":"Immunotherapy"},{"key":"99_CR79","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1056\/NEJMoa1215739","volume":"369","author":"WJ Sandborn","year":"2013","unstructured":"Sandborn WJ, Feagan BG, Rutgeerts P, Hanauer S, Colombel JF, Sands BE, et al. Vedolizumab as induction and maintenance therapy for Crohn\u2019s disease. N Engl J Med. 2013;369:711\u201321.","journal-title":"N Engl J Med"},{"key":"99_CR80","doi-asserted-by":"crossref","unstructured":"Feagan BG, Rutgerrts P, Sands BE, Hanauer S, Colombel JF, Sandborn WJ, Van Assche G, axler J, Kim HF, Danese S, Fox I, Milch C, Sankoh S, Wyant T, Xu J, Parikh A. Vedlizumab as induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2013; 369-699-710.","DOI":"10.1056\/NEJMoa1215734"},{"key":"99_CR81","doi-asserted-by":"publisher","first-page":"1912","DOI":"10.1056\/NEJMoa043335","volume":"353","author":"WJ Sandborn","year":"2005","unstructured":"Sandborn WJ, Colombel JF, Enns R, Feagan BG, Hanauer SB, Lawrance IC, et al. Natalizumab induction and maintenance therapy for Crohn\u2019s disease. N Engl J Med. 2005;353:1912\u201325.","journal-title":"N Engl J Med"},{"key":"99_CR82","doi-asserted-by":"publisher","first-page":"1672","DOI":"10.1053\/j.gastro.2007.03.024","volume":"132","author":"SR Targan","year":"2007","unstructured":"Targan SR, Feagan BG, Fedorak RN, Lashner BA, Panaccione R, Present DH, et al. Natalizumab for treatment of active Crohn\u2019s disease: results of the ENCORE Trial. Gastroenterology. 2007;132:1672\u201383.","journal-title":"Gastroenterology"},{"key":"99_CR83","unstructured":"Yajnik V, Khan N, Dubinsky M, et al. Efficacy and safety of vedolizumab with advancing age in patients with ulcerative colitis: results from the GEMINI I study [poster Sa1274]. Poster presented at: 2015 Digestive Disease Week (DDW); 2015; Washington, DC"},{"key":"99_CR84","volume-title":"Efficacy and safety of vedolizumab with advancing age in patients with Crohn\u2019s disease: results from the GEMINI 2 study [poster P1764]","author":"V Yajnik","year":"2015","unstructured":"Yajnik V, Khan N, Dubinsky M, et al. Efficacy and safety of vedolizumab with advancing age in patients with Crohn\u2019s disease: results from the GEMINI 2 study [poster P1764]. Honolulu: Poster presented at: 2015 American College of Gastroenterology Annual Scientific Meeting; 2015."},{"key":"99_CR85","doi-asserted-by":"publisher","first-page":"193","DOI":"10.2165\/11531490-000000000-00000","volume":"27","author":"R Stahlmann","year":"2010","unstructured":"Stahlmann R, Lode H. Safety considerations of fluoroquinolones in the elderly: an update. Drugs Aging. 2010;27:193\u2013209.","journal-title":"Drugs Aging"},{"key":"99_CR86","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/j.exger.2014.05.013","volume":"57","author":"A Cios","year":"2014","unstructured":"Cios A, Wyska E, Szymura-Oleksiak J, Grodzicki T. Population pharmacokinetic analysis of ciprofloxacin in the elderly patients with lower respiratory tract infections. Exp Gerontol. 2014;57:107\u201313.","journal-title":"Exp Gerontol"},{"key":"99_CR87","doi-asserted-by":"publisher","first-page":"361","DOI":"10.7326\/0003-4819-88-3-361","volume":"88","author":"S Frytak","year":"1978","unstructured":"Frytak S, Moertel CH, Childs DS. Neurologic toxicity associated with high-dose metronidazole therapy. Ann Intern Med. 1978;88:361\u20132.","journal-title":"Ann Intern Med"},{"key":"99_CR88","doi-asserted-by":"publisher","first-page":"679","DOI":"10.2165\/00003495-199754050-00003","volume":"54","author":"CD Freeman","year":"1997","unstructured":"Freeman CD, Klutman NE, Lamp KC. Metronidazole. A therapeutic review and update. Drugs. 1997;54:679\u2013708.","journal-title":"Drugs"},{"key":"99_CR89","doi-asserted-by":"publisher","first-page":"680","DOI":"10.1053\/j.gastro.2008.01.004","volume":"134","author":"GG Kaplan","year":"2008","unstructured":"Kaplan GG et al. Impact of hospital volume on postoperative morbidity and mortality following a colectomy for ulcerative colitis. Gastroenterology. 2008;134:680\u20137.","journal-title":"Gastroenterology"},{"key":"99_CR90","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1001\/archsurg.2011.194","volume":"146","author":"GG Kaplan","year":"2011","unstructured":"Kaplan GG et al. Risk of comorbidities on postoperative outcomes in patients with inflammatory bowel disease. Arch Surg. 2011;146:959\u201364.","journal-title":"Arch Surg"},{"issue":"Suppl 1","key":"99_CR91","first-page":"S245","volume":"142","author":"C Ha","year":"2012","unstructured":"Ha C, Payless T, Wick E. Increased incidence of postoperative complications in older inflammatory bowel disease patients having intestinal surgery [abstract 104]. Gastroenterology. 2012;142 Suppl 1:S245.","journal-title":"Gastroenterology"},{"key":"99_CR92","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1007\/s11894-012-0310-4","volume":"15","author":"CY Ha","year":"2013","unstructured":"Ha CY, Katz S. Clinical outcomes and management of inflammatory bowel disease in the older patient. Curr Gastroenterology Rep. 2013;15:310.","journal-title":"Curr Gastroenterology Rep."},{"key":"99_CR93","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1007\/s00595-013-0563-z","volume":"44","author":"H Ikeuchi","year":"2014","unstructured":"Ikeuchi H, Uchino M, Matsuoka H, et al. Prognosis following emergency surgery for ulcerative colitis in elderly patients. Surg Today. 2014;44:39\u201343.","journal-title":"Surg Today"},{"key":"99_CR94","doi-asserted-by":"publisher","first-page":"1435","DOI":"10.1007\/s10620-012-2100-0","volume":"57","author":"W Blonski","year":"2012","unstructured":"Blonski W, Lichenstein GR. Survival in elderly patients with ulcerative colitis and colorectal cancer. Dig Dis Sci. 2012;57:1435\u20138.","journal-title":"Dig Dis Sci"},{"issue":"5","key":"99_CR95","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1111\/apt.12616","volume":"39","author":"JP Gisbert","year":"2014","unstructured":"Gisbert JP, Chaparro M. Systematic review with meta-analysis: inflammatory bowel disease in the elderly. Ailment Pharmacol Ther. 2014;39(5):459\u201377.","journal-title":"Ailment Pharmacol Ther"},{"key":"99_CR96","doi-asserted-by":"publisher","first-page":"1351","DOI":"10.1016\/j.crohns.2014.05.006","volume":"8","author":"D Duricova","year":"2014","unstructured":"Duricova D, Burisch J, Jess T, Gower-Rousseau CG, Lakatos PL. Age-related differences in presentation and course of inflammatory bowel disease: an update on the population-based literature. J Crohn\u2019s Colitis. 2014;8:1351\u201361.","journal-title":"J Crohn\u2019s Colitis"},{"key":"99_CR97","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1038\/ajg.2012.429","volume":"108","author":"YR Wang","year":"2013","unstructured":"Wang YR, Cangemi JR, Loftus Jr EV, Picco MF. Rate of early\/missed colorectal cancers after colonoscopy in older paitents with or without inflammatory bowel disease in the United States. Am J Gastroenterol. 2013;108:444\u20139.","journal-title":"Am J Gastroenterol"},{"key":"99_CR98","doi-asserted-by":"publisher","first-page":"656","DOI":"10.1055\/s-2008-1077445","volume":"40","author":"G Terheggen","year":"2008","unstructured":"Terheggen G, Lanyi B, Schanz S, et al. Safety, feasibility, tolerability of ileocolonoscopy in inflammatory bowel disease. Endoscopy. 2008;40:656\u201363.","journal-title":"Endoscopy"},{"key":"99_CR99","doi-asserted-by":"publisher","first-page":"849","DOI":"10.7326\/0003-4819-150-12-200906160-00008","volume":"150","author":"JL Warren","year":"2009","unstructured":"Warren JL, Klabunde CN, Mariotto AB, et al. Adverse events after outpatient colonoscopy in the Medicare population. Ann Intern Med. 2009;150:849\u201357. W152.","journal-title":"Ann Intern Med"},{"key":"99_CR100","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1016\/j.gie.2008.09.008","volume":"69","author":"G Arora","year":"2009","unstructured":"Arora G, Mannalithara A, Singh G, et al. Risk of perforation from a colonoscopy in adults: a large population-based study. Gastrointest Endosc. 2009;69:654\u201364.","journal-title":"Gastrointest Endosc"},{"key":"99_CR101","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1016\/j.gie.2011.06.023","volume":"74","author":"LW Day","year":"2011","unstructured":"Day LW, Kwon A, Inadomi JM, et al. Adverse events in older patients undergoing colonoscopy: a systematic review and meta-analysis. Gastrointest Endosc. 2011;74:885\u201396.","journal-title":"Gastrointest Endosc"},{"issue":"1","key":"99_CR102","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.cger.2013.10.002","volume":"30","author":"HA Horton","year":"2014","unstructured":"Horton HA, Kim H, Melmed GY. Vaccinations in older adults with gastrointestinal diseases. Clin Geriatr Med. 2014;30(1):17\u201328.","journal-title":"Clin Geriatr Med"},{"issue":"7","key":"99_CR103","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1016\/j.mayocp.2015.04.021","volume":"90","author":"TC Cheetham","year":"2015","unstructured":"Cheetham TC, Marcy SM, Tseng HF, Sy LS, Liu IL, Bixler F, et al. Risk of herpes zoster and disseminated varicella zoster in patients taking immunosuppressant drugs at the time of zoster vaccination. Mayo Clin Proc. 2015;90(7):865\u201373.","journal-title":"Mayo Clin Proc"},{"key":"99_CR104","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1016\/j.cgh.2010.04.023","volume":"8","author":"GY Melmed","year":"2010","unstructured":"Melmed GY, Spiegel BM, Bressler B, et al. The appropriateness of concomitant immunomodulators with anti-tumor necrosis factor agents for Crohn\u2019s disease: 1 size does not fit all. Clin Gastroenterol Hepatol. 2010;8:655\u20139.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"99_CR105","doi-asserted-by":"publisher","first-page":"2272","DOI":"10.1111\/j.1572-0241.2008.02052.x","volume":"103","author":"GC Nguyen","year":"2008","unstructured":"Nguyen GC, Sam J. Rising prevalence of venous thromboembolism and its impact on mortality among hospitalized inflammatory bowel disease patients. Am J Gastroenterology. 2008;103:2272\u201380.","journal-title":"Am J Gastroenterology"}],"container-title":["Current Treatment Options in Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11938-016-0099-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11938-016-0099-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11938-016-0099-6","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11938-016-0099-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,29]],"date-time":"2022-07-29T11:20:00Z","timestamp":1659093600000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11938-016-0099-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,7,7]]},"references-count":105,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2016,9]]}},"alternative-id":["99"],"URL":"https:\/\/doi.org\/10.1007\/s11938-016-0099-6","relation":{},"ISSN":["1092-8472","1534-309X"],"issn-type":[{"value":"1092-8472","type":"print"},{"value":"1534-309X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,7,7]]},"assertion":[{"value":"7 July 2016","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"Elizabeth S. John declares that she has no conflict of interest.Kristina Katz declares that she has no conflict of interest.Mark Saxena declares that he has no conflict of interest.Sita Chokhavatia declares that she has no conflict of interest.Seymour Katz declares that he has no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This article does not contain any studies with human or animal subjects performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights and Informed Consent"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}]}}